Ohio Clinical Trials (OCT)

OCT specializes in optimizing the design and execution of Phase I studies, ensuring efficiency and cost-effectiveness. Additionally, with extensive expertise in Phase II and III studies, OCT collaborates with specialists across diverse therapeutic areas to deliver exceptional results.

Lock In Your Beds For Your Next Clinical Study

Let’s discuss your upcoming studies and secure the space you need. We also welcome you to schedule a tour to explore our capabilities and meet our expert team in person.

Over 60 Beds

OCT by the Numbers

0 +

Square Feet

0 +

Private Rooms for Special Populations

0 +

Beds

< 0 Miles

From the nearest emergency room

0 Million

Metropolitan-area residents

0 +

Pre-identified overweight or obese candidates

0 +

Pre-identified subjects for HAP/HAL studies

> 0 %

Average historical retention rate

More About the Phase I Facility

On-site processing laboratory, with a -70º C freezer and two -20º C freezers and a variable temperature freezer that can accommodate up to -80º C
Computerized temperature/humidity monitoring system for selected rooms, freezers, and refrigerators, with programmed alerts
Multiple monitor rooms
Pharmacy cleanroom suite with Class 5 hood
Telemetry capabilities
Experienced pharmacy team in product preparation and administration including injectables (IV, IM, subcutaneous), over-encapsulation, and nasal insufflation

Brain Mapping (EEG/qEEG)

Cardiac Telemetry, Thorough QT/QTC, and Continuous Pulse Oximetry

Opioid-induced Respiration Depression (OIRD) as a model to test opioid antagonists

Abuse Liability Trials

Ohio Clinical Trials has over 20 years of experience conducting human abuse liability / human abuse potential trials. The clinical and pharmacy team are comfortable with all types of HAP/HAL product formulations (oral, IV, intranasal). Additionally, the site has conducted complex respiratory depression trials for over 10 years with recreational opioid users.

OCT has an unmatched understanding of the optimal design, planning, and execution of every detail of these types of trials, including the following substances:

Engage with Industry-Leading Researchers

Glen Apseloff, MD, FCP

Founder & Investigator

Drawing on over 30 years of clinical trial experience, Dr. Apseloff serves as a consulting investigator, providing guidance on all aspects of trial execution. In addition to working with a wide variety of medical specialists, Dr. Apseloff collaborates with experts/specialists from Dentistry (maxillofacial surgery), Optometry, Pharmacy, and Veterinary Medicine.

Angela Eakin, MD, MS, DipABLM

Principal Investigator

Dr. Eakin serves as the principal investigator on every study at OCT and specializes in streamlining the design and execution of Phase I studies. She has experience in shaping protocols to maximize efficiency while minimizing costs and shortening timelines. She also has expertise in Phase II and III studies and has access to specialists in a broad range of therapeutic areas.